Clinical Trial Detail

NCT ID NCT03847519
Title Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Advaxis, Inc.
Indications

lung non-small cell carcinoma

Therapies

ADXS-503 + Pembrolizumab

ADXS-503

Age Groups: senior adult

Additional content available in CKB BOOST